At 55.4% CAGR Transthyretin Amyloidosis Treatment Market To Reach US$ 1,218.3 Million By 2026
Global Transthyretin Amyloidosis Treatment Market, by Drug Type (Tafamidis (Vyndaqel), Patisiran (ONPATTRO), Inotersen (TEGSEDI), and Others), By Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, and Mixed) and Wild Type), and by Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is expected to be valued at US$ 35.8 million in 2018 and is estimated to exhibit a CAGR of 55.4% over the forecast period (2018-2026), as highlighted in a new report published by Coherent Market Insights.
Request to download and view Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/687
The increasing launches and regulatory approval of novel therapies indicated for the treatment of transthyretin amyloidosis are expected to drive growth of the market over the forecast period. For instance, in October 2018, Alnylam Pharmaceuticals, Inc. launched ONPATTRO (patisiran) in Germany. The drug is indicated for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults with stage 1 or stage 2 polyneuropathy. Moreover, in October 2018, Ionis Pharmaceuticals, Inc. and Akcea Therapeutics, Inc. received the U.S. Food and Drug Administration (FDA) approval for novel drug TEGSEDI (inotersen), which is indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
In addition, manufacturers in market are focused on developing novel therapies and are expected to gain approval in the near future. Thus, presence of such robust pipeline is one the major factors that is expected to drive the market growth over the forecast period. For instance, in March 2018, Pfizer, Inc. reported positive results from Phase 3 ATTR-ACT study of Tafamidis among patients suffering from transthyretin cardiomyopathy.
Browse 35 Market Data Tables and 43 Figures spread through 221 Pages and in-depth TOC on Global Transthyretin Amyloidosis Treatment Market, by Drug Type (Tafamidis (Vyndaqel), Patisiran (ONPATTRO), Inotersen (TEGSEDI), and Others), by Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, and Mixed) and Wild Type), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) – Forecast to 2026
To know the latest trends and insights prevalent in the Global Transthyretin Amyloidosis Treatment Market press release, click the link below: https://www.coherentmarketinsights.com/press-release/transthyretin-amyloidosis-treatment-market-to-surpass-us-12183-million-threshold-by-2026-1181
Key players in the market are focusing on adopting mergers and partnerships growth strategies, in order to strengthen their market position. For instance, in October 2018, Ionis Pharmaceuticals, Inc. and Akcea Therapeutics, Inc. entered into a distribution agreement with Accredo specialty pharmacy, a subsidiary of Express Scripts to distribute TEGSEDI (inotersen) subcutaneous injection indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. Moreover, in August 2018, Alnylam Pharmaceuticals, Inc. entered into a partnership with US Bioservices, a specialty pharmacy and a part of AmerisourceBergen, to dispense ONPATTRO (patisiran) lipid complex injection.
Transthyretin amyloidosis is a rare disease and its symptoms are not easily identified. Hence it is diagnosed late, which in turn negatively affects the course of action in terms of treatment. For instance, according to the data published by The American Journal of Managed Care in 2017, hereditary transthyretin-mediated (hATTR) amyloidosis affected around 50,000 patients, globally. However, the diagnosis rate of transthyretin amyloidosis is very low. For instance, according to a study published by Alnylam Pharmaceuticals, Inc., in January 2018, the diagnosis rate of hATTR in the U.S. was around ~10-30%, and this is expected to hamper growth of the market over the forecast period.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/687
Key Takeaways of the Global Transthyretin Amyloidosis Treatment Market:
- The global transthyretin amyloidosis treatment market is expected to exhibit a CAGR of 55.4% over the forecast period, attributed to product launches by key players such as Alnylam Pharmaceuticals, Inc. and Ionis Therapeutics, among others
- Among regions, North America is expected to hold a dominant position in the global transthyretin amyloidosis treatment market over the forecast period, attributed to regulatory approvals and launch of new products in the region. For instance, in June 2017, Pfizer Inc. received the U.S. Food and Drug Administration (FDA) Fast Track designation for its Tafamidis, the company’s investigational treatment therapy for Transthyretin Cardiomyopathy (TTR-CM).
- Moreover, Asia Pacific is expected to witness significant growth in the market over the forecast period, owing to increasing regulatory approvals of novel therapies in the region. For instance, in March, 2018, the Ministry of Health Labor and Welfare in Japan granted SAKIGAKE designation to Pfizer Inc.’s Tafamidis, for the treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM).
- However, there are no approved drugs available for the treatment of cardiomyopathy. Therefore, key players in the market are focusing to receive approval for their drugs for cardiomyopathy indication, in order to launch their drugs in key regions such as the U.S. to strengthen their market position. Similarly to cardiomyopathy, no specifically approved drug is available for the treatment of wild-type transthyretin amyloidosis. Therefore, key players are focusing to develop drugs for the treatment of wild type disease to gain high revenue and market share.
- Key players operating in the global transthyretin amyloidosis treatment market include Alnylam Pharmaceuticals, Inc., Pfizer, Inc., Prothena Corporation Plc., GlaxoSmithKline Plc., Ionis Pharmaceuticals, Inc., Eidos Therapeutics, and SOM Innovation Biotech, S.L.
Special Requirements?
We value your investment and offer customization as per your requirements.
Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/687
Table of Contents
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Disease Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Geography
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Clinical Characteristics
- Disease Diagnosis
- Treatment Overview
- Mechanism Of Action
- Pipeline Analysis
- Product Approval/Launches
- Partnership- Collaboration Scenario
- Epidemiology
- Pest Analysis
- Porter’s Five Forces Analysis
- Drivers
- Restraints
- Market Opportunities
- Market Dynamics
- Global Transthyretin Amyloidosis Treatment Market, By Drug Type, 2016–2026 (US$ Mn)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017–2026
- Segment Trends
- Tafamidis (Vyndaqel)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
- Patisiran (ONPATTRO)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
- Inotersen (TEGSEDI)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
- Introduction
- Global Transthyretin Amyloidosis Treatment Market, By Disease Type, 2016–2026 (US$ Mn)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017–2026
- Segment Trends
- Hereditary Transthyretin Amyloidosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
- Polyneuropathy
- Cardiomyopathy
- Mixed Type
- Wild Type Amyloidosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
- Introduction
- Global Transthyretin Amyloidosis Treatment Market, By Distribution Channel, 2016–2026 (US$ Mn)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017–2026
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
- Specialty Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
- Introduction
- Global Transthyretin Amyloidosis Treatment Market, By Geography, 2016 – 2026 (US$ Mn)
- Introduction
- Market Share Analysis, By Geography, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, For Geography, 2017–2026
- North America
- Market Size and Forecast, By Drug Type, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Drug Type, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Type, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, By Drug Type, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Africa
- Market Size and Forecast, By Drug Type, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
- Central Africa
- South Africa
- North Africa
- Middle East
- Market Size and Forecast, By Drug Type, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Introduction
- Competitive Landscape
- Company Profiles
- Alnylam Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Ionis Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer, Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eidos Therapeutics, Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Akcea Therapeutics, Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Prothena Corporation Plc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline Plc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- SOM Innovation Biotech, S.L.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Alnylam Pharmaceuticals, Inc.
- Company Profiles
- Section
- References
- Research Methodology
- About Us and Sales Contact
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
Editor Details
-
Company:
- CDN Newswire
